| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 600.52M | 432.50M | 621.61M | 896.29M | 820.24M | 624.36M |
| Gross Profit | 118.50M | 51.27M | 141.57M | 148.86M | 204.66M | 155.47M |
| EBITDA | 70.52M | 46.98M | 91.29M | 133.56M | 90.27M | 95.85M |
| Net Income | 53.64M | 40.17M | 70.53M | 100.01M | 67.19M | 74.38M |
Balance Sheet | ||||||
| Total Assets | 459.71M | 428.32M | 471.21M | 597.27M | 541.39M | 518.20M |
| Cash, Cash Equivalents and Short-Term Investments | 228.56M | 269.58M | 311.26M | 272.02M | 226.22M | 201.51M |
| Total Debt | 13.48M | 14.56M | 17.13M | 22.20M | 8.45M | 18.03M |
| Total Liabilities | 186.40M | 136.70M | 132.12M | 252.33M | 257.39M | 225.23M |
| Stockholders Equity | 273.31M | 291.63M | 339.09M | 344.94M | 284.00M | 292.97M |
Cash Flow | ||||||
| Free Cash Flow | 52.79M | 43.30M | 109.91M | 86.72M | 99.96M | 37.11M |
| Operating Cash Flow | 53.72M | 45.05M | 113.30M | 90.99M | 106.42M | 41.90M |
| Investing Cash Flow | -413.00K | -122.64M | 29.05M | -13.70M | -34.45M | -4.10M |
| Financing Cash Flow | -41.72M | -91.80M | -83.08M | -43.48M | -75.36M | 151.92M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | S$894.03M | 23.58 | 9.11% | 1.88% | 11.57% | 0.89% | |
71 Outperform | S$574.99M | 14.52 | 12.72% | 17.05% | -50.75% | -61.46% | |
69 Neutral | S$335.70M | 11.65 | 70.97% | 5.52% | 32.76% | 54.96% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | S$936.43M | 55.29 | 2.87% | ― | 4.60% | ― | |
54 Neutral | S$433.40M | 36.11 | 3.50% | 1.12% | 22.66% | 83.49% |
Aztech Global’s Malaysian manufacturing arm, IOT Manufacturing Sdn. Bhd., has secured U.S. FDA establishment registration under 21 CFR Part 807 for its Pasir Gudang facility, adding to its existing ISO 13485 certification for medical devices. The move strengthens Aztech’s bid to become a preferred manufacturing partner for medical device owners targeting the U.S. market, leveraging its large-scale, 300,000-square-foot plant, integrated packaging capabilities and experience in IoT production to offer compliant, rapid industrialisation and commercial supply, which could deepen its role in the medical technology supply chain and broaden its U.S.-focused revenue streams.
The most recent analyst rating on (SG:8AZ) stock is a Hold with a S$0.66 price target. To see the full list of analyst forecasts on Aztech Global Ltd. stock, see the SG:8AZ Stock Forecast page.
Aztech Global Ltd. has announced the completion of a sale-and-leaseback transaction involving its factory buildings and land in Dongguan, China, executed through a wholly owned subsidiary. The deal allows the company to unlock capital tied up in its industrial property while retaining operational use of the facilities through a leaseback arrangement, potentially enhancing financial flexibility without disrupting ongoing manufacturing activities at the Dongguan site.
The most recent analyst rating on (SG:8AZ) stock is a Hold with a S$0.66 price target. To see the full list of analyst forecasts on Aztech Global Ltd. stock, see the SG:8AZ Stock Forecast page.
Aztech Global Ltd. has announced that its wholly-owned subsidiary Aztech DG and the purchaser of a property in its sale-and-leaseback transaction have mutually agreed to complete the sale in January 2026. This revised completion timeline clarifies the schedule of the previously announced deal and provides stakeholders with an updated timeframe for when the property transaction, and the associated capital and operational implications of the sale-and-leaseback, will take effect.
The most recent analyst rating on (SG:8AZ) stock is a Hold with a S$0.66 price target. To see the full list of analyst forecasts on Aztech Global Ltd. stock, see the SG:8AZ Stock Forecast page.